Introduction
Evaluation of genetic toxicity is an important component of the safety assessment of chemicals, including pharmaceuticals, agricultural chemicals, food additives and industrial chemicals. Up to the present time, genotoxicity has been regulated mainly on the basis of qualitative outcomes of hazard identification assays, i.e. decisions are often based on classification as positive or negative for genotoxic potential. Recently, the field is moving towards quantitative risk assessments and with more reliance on weight of evidence (WOE) approaches (1) (2) (3) . In vivo assays are critical components of both WOE analysis and of quantitative risk assessments. The in vivo micronucleus (MN) assay using rodent haematopoietic cells from bone marrow or peripheral blood is widely used for the assessment of clastogenicity/aneugenicity of chemicals, both as a hazard screening assay and as a component of exposure-based risk assessments. The assay is usually incorporated into the standard genotoxicity test battery as a representative in vivo assay together with an in vitro gene mutation assay using bacteria and an in vitro chromosomal aberration assay using cultured mammalian cells (4) . The MN assay was originally established using rodent erythrocytes as a simple method of assessing cytogenetic damage, taking advantage of two important characteristics of the haematopoietic system: (i) the ease of scoring MN in the newly formed anucleate reticulocytes derived from bone marrow and (ii) the ability to identify the newly formed erythrocytes that had completed their last division during or shortly after exposure to the test agent as those staining positive for RNA content (5, 6) . These important advantages initially led to an almost exclusive focus on the haematopoietic cells as the target. However, in principle, MN can be scored in any dividing cell population, and the assay was soon extended to tissues other than bone marrow.
One of the early extensions of the assay was to male germ cells, which are a key cell population for genetic studies and which undergo continuous active division (7, 8) . The assay was also extended to liver by stimulating regeneration and hence cell replication, by partial hepatectomy (9) (10) (11) (12) or pretreatment with hepatotoxicants (13, 14) . Later, colon, skin and young rodent liver were studied extensively and shown to be suitable for MN analysis. Studies using human tissues or cell preparations include corneal cells and exfoliated cells from urinary bladder, oesophagus, cells of the nasal cavity and oral buccal mucosa (15, 16) . Rodent embryonic cells have also been used to evaluate effects of transplacental application of test chemicals. In addition, human lymphocytes have been used to assess cytogenetic damage in epidemiology studies of environmentally or occupationally exposed individuals, as summarised previously. The MN assay using peripheral lymphocytes or other human tissues is reviewed separately in this special issue.
In regulatory testing, the rodent erythrocyte MN assay is the most common first choice among in vivo assays used for subsequent testing when in vitro genotoxicity test(s) are found to be positive. The unscheduled DNA synthesis assay using rat liver has also been used in this situation, but its sensitivity has been questioned (17) . The single-cell gel electrophoresis (comet) assay and gene mutation assays using transgenic animals are frequently considered for use as follow-up assays when in vitro gene mutation assay(s) are positive. It is important to evaluate cytogenetic damage in those cell populations or tissues that are the relevant sites of distribution and metabolism in vivo, and so bone marrow haematopoietic cells alone cannot satisfy this need.
Scientific considerations as well as the animal welfare movement, which emphasises the reduction, replacement and/ or refinement of animal use (the '3Rs'), have contributed to the implementation of protocols that allow the integration of genotoxicity end points into general toxicological tests. Assays that have been shown to be appropriate for integration with repeat-dose general toxicology studies include the bone marrow and peripheral blood erythrocyte MN assays, the peripheral blood lymphocyte assay and a new MN assay method using rat liver after an extended period of repeated dosing (18) . The liver is a key site of xenobiotic metabolism and accumulation in vivo, and therefore the repeat-dose method, which appears to be applicable in adult rats, promises to be an important assay that could be incorporated into general toxicological studies.
MN assays using tissues other than bone marrow have previously been reviewed in conjunction with two International Workshops on Genotoxicity Testing (IWGT) (19, 20) and have been discussed by Kirkland et al. (17, 21) . Here, we update the previous publications of the IWGT groups and revise the previous table of assay results to include studies published after 2000.
Literature search
The literature search was conducted by using PubMed (http:// www.ncbi.nlm.nih.gov/sites/entrez) and search terms that included 'micronucleus', 'rat', 'mouse' and specific tissue names with limitations of year and English language. The time limit was from 2000 to present, except for colon, liver and skin, in which cases the limit was set to 2005 or later because these tissues were evaluated in the third and fourth IWGT reviews (19, 20) . All abstracts identified in the searches were reviewed and then suitable articles were selected for further review and inclusion. Certain literature, for example publications of in vitro or in vivo studies of irradiation (e.g. X-ray, magnetic field), some MN studies on mouse models of human genetic disease or dietary deficiency and human studies were excluded. The tissues identified in which the rodent MN assays had been reported were alveolar, bladder, buccal mucosa, colon, liver, skin, spleen, stomach, vagina and foetal or neonatal tissues. No additional literature related to sperm or spermatid MN assays after 2000 was found. The identified assay results published within the above time periods are listed in Table I .
MN assays using tissues other than bone marrow
Liver Liver is often a site of carcinogenic response, but liver cells replicate relatively slowly in adult animals. Therefore, in the early development stage of the liver MN assay, cell division was stimulated by partial hepatectomy (9) (10) (11) (12) or treatment with hepatotoxicants (13, 14) . Early protocols were improved by subsequent investigators (25, 59) who recognised that in rodents there is active cell division in liver soon after birth, i.e. up to 5-6 weeks in rat. Based on this characteristic, young rats (22, 23, 26, 27, 29) or mice (28) can be used for MN frequency determination without any additional physical or chemical treatment.
As noted above, recently a new protocol using adult rat liver in combination with repeated treatments is now under development (Narumi et al., submitted for publication). This method should be easily integrated with general toxicological studies. As an example, adult rats that received daily Nnitrosodiethylamine (DEN) or 2,4-diaminotoluene (2,4-DAT) for 5, 14 and 28 days orally without any additional treatment had elevated frequencies of micronucleated hepatocytes after repeated treatments with DEN for !5 days or with 2,4-DAT for !14 days. The observed frequencies increased with the number of treatments, as expected. To verify the reliability of this method, cell proliferation in liver has been investigated with bromodeoxyuridine intake. Atrazine also induced MN in rat liver treated for 21 days (24) . This method promises to allow monitoring of genetic damage in this important tissue during routine repeated-dose toxicology assays.
Colon and intestinal epithelium
The colon and digestive tract are important target sites of carcinogens (e.g. hydrazines). In addition, colon is an important tissue for metabolism by the intestinal microflora and excretion by feces (30) . Therefore, the MN assay in colon and/or intestine is appropriate for hazard identification and risk evaluation of environmental chemicals that enter the human body through the food chain, such as pesticides and food ingredients, as well as for orally administrated pharmaceuticals (33) . The colon MN assay with the mouse was developed by Goldberg et al. (60) , and it has been improved by Vanhauwaert et al. (61) and Ohyama et al. (62) . The colon MN assay has been used for the confirmation of the presence or absence of genotoxic activity in colon (30) (31) (32) (33) . Because cells in the colon originate from stem cells at the base of the crypts that are vascularised, it is also possible that MN in colon cells may be induced via blood-borne genotoxicants.
Skin
Skin is the major site of exposure to many chemicals, including industrial chemicals, pesticides, consumer products, cosmetics and pharmaceuticals. Skin is also an important tissue for protection from environmental agents, including light and chemicals. Although the use of in vitro photo-genotoxicity assays is diminishing because of oversensitivity and low specificity, the skin MN assay provides a more relevant method of assessing the risk of in vivo photo-genotoxicity associated with exposure to chemical and physical agents (35, 36) . The skin MN assay in the mouse was introduced around 1990 (63, 64) , and it was then developed in the rat and hairless mouse by Nishikawa et al. (34, 65, 66) . In this assay, acridine orange fluorescent staining is playing an important role not only to identify MN but also to identify the appropriate cell population to be analyzed (34, 35) . Although many studies have been conducted using skin application with or without ultraviolet irradiation, detection of systemic effects in skin following oral administration is also important (67) .
Spleen
The spleen MN assay with mouse splenocytes has been developed by Shindo et al. (68) , using splenocytes as the target cell population. Evaluation of genotoxic effects in splenocytes during subchronic exposures provides another relevant target tissue in addition to haematopoietic cells in bone marrow or peripheral blood (37) (38) (39) (40) . In vitro and/or in vivo methods have been used in many studies (38, (40) (41) (42) .
Lung
Lung is one of the major target sites of those carcinogens for which inhalation is the major route of exposure. Therefore, lung cells are an important target site for detection of local genotoxic effects of environmental or industrial chemicals following or during inhalation exposures (43, (45) (46) (47) . Intratracheal instillation is also often used as a means of delivery to the lung in animal experiments (43) . Studies of long-term exposure (several weeks or months) by inhalation are also possible (44, 47) . A lung MN assay was developed as an in vivo/in vitro assay in early 1990s (69, 70) , and in more recent 
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et al. studies, several types of lung cells have been used, including bronchoalveolar lavage cells, alveolar type II cells, Clara cells or pulmonary alveolar macrophages
Stomach
Stomach is important because it is the first site of direct contact of many chemicals. Several in vivo genotoxicity assays using stomach have been developed, including the unscheduled DNA synthesis assay, comet assay and transgenic mutation assay. Recently, a stomach MN assay has been established by Okada et al. (48) . Though data obtained are at present limited to two known stomach carcinogens (N-methyl-N#-nitro-N-nitrosoguanidine and N-nitroso-N-methylurea) , the assay appears promising for further development.
Bladder Urinary bladder is a tumour target site of certain chemical classes such as naphthylamines, benzidines or aminobiphenyls. Because it is the tissue that collects urine excreted by kidneys, it will be exposed to water-soluble chemicals excreted via the urine. A bladder MN assay has been developed as a tool for studies of cancer risk, including intervention studies, in humans (71) . Exfoliated or epithelial cells from urinary bladder have also been used in animal studies in which acute or subchronic exposures by several routes of administration were employed (32, 44, (49) (50) (51) . The bladder MN assay is a good biomonitoring tool for humans exposed to carcinogenic or genotoxic chemicals, and analogous studies with animals can be used for identification and/or confirmation of genotoxic action in the bladder.
Buccal mucosa
Buccal mucosal cells have been used for biomonitoring of DNA damage potentially leading to oral cancer in humans (15, 72) . Although many studies have been conducted in humans, animal data are scant (52) or limited to animal models of human disease such as Alzheimer's disease (73) . This may indicate that analysis of MN in buccal mucosal cells in rodents may not be suitable at present for detection of genotoxic effects and that technical development will be needed for general use of the detection of local genotoxic effects at this site in animals.
Vagina
Carcinoma of the uterine cervix is important in humans and has been shown to be inducible by chemical exposure in the mouse (55) . A vaginal MN assay could be a useful tool for screening new chemopreventive agents in the rodent. Chakrabarti and Dutta (74) described a vaginal MN assay that could detect known MN inducers, but there is not yet sufficient data to evaluate the utility of this model (53) (54) (55) (56) .
Foetal/neonatal tissues Assays using MN induction to evaluate transplacental genotoxicity were developed around 1980 (75) (76) (77) and many studies were published before 2000. Those studies have been summarised in previous IWGT reports (19, 20) . In the late 1980s, MacGregor et al. (78, 79) showed that additional kinetic information could be obtained in the foetal blood MN assay by categorising newly formed red blood cells into age groups based on RNA aggregation state. Additional data from studies using peripheral blood from neonates or peripheral blood and liver from foetuses, found in our search of the literature published after 2005 are summarised in Table I (57, 58) . Foetal/ neonatal MN assays using transplacental exposure will be useful for evaluation of agents associated with embryotoxicity, congenital malformations, tumours, heritable mutations in germ cells or other adverse developmental effects.
Spermatogonia/spermatids A spermatogonial MN assay was proposed in the early 1980s (7, 8) , and early results of this assay were summarised in the previous IWGT reports (19, 20) . No new data were identified in our PubMed search. Initially, it was difficult to identify the specific developmental stage of spermatogonial cells and to restrict the cell population to be analysed. A fluorescent staining method using acridine orange and 4#,6-diamino-2-phenylindole concomitantly has now been introduced and it facilitates identification of the spermatogonial cells to be analysed (80) . This staining method has also been applied to other tissues successfully because the cytoplasm and nucleus are clearly stained and provide increased accuracy of scoring micronucleated cells.
The evaluation of MN in reproductive tissue is obviously important in the evaluation of adverse effects to subsequent generations. The United Nations (UN) 'Globally Harmonised System of Classification and Labelling of Chemicals (GHS)' requests hazard classification of chemicals based on germ cell mutagenicity (81, 82) and identifies the spermatid MN assay as an example of a mutagenicity test applicable to germ cells.
Discussion
Many tissues other than bone marrow or peripheral blood have been used for evaluation of MN frequencies in vivo in rodents. In our literature search, liver, colon epithelium, skin, spleen, lung, stomach, bladder, buccal mucosa, vagina and foetal/neonatal tissues were identified as target tissues used for such assays. No new data on MN incidence in spermatogonia or spermatids were identified after the previous IWGT reviews (19, 20) . These MN assays have been used to detect local or systemic genotoxic effect in important tissues, including germ cells and progeny.
These assays are important tools for the prediction and evaluation of chemical carcinogenicity and also for the identification and study of agents with the potential to induce transmissible germ line mutations. Currently, there is emphasis on extending hazard identification techniques to evaluate genotoxic risk more quantitatively (1, 2, 83) . One important objective of genotoxicity evaluation is the assessment of the mechanism of carcinogenicity, and whether genotoxic mechanisms are involved or not. Another is to assess adverse heritable effects of chemicals that may appear in subsequent generations. For the former purpose, assays are needed that permit assessment in the appropriate target tissues and allow development of mode of action (MOA) and a WOE of information in conjunction with information about exposure and metabolic transformation (84) . The tissues with most active cell division are bone marrow, gastrointestinal tract, skin and reproductive tissues in mammals. These tissues have been used as experimental materials for the analysis of chromosomal damage, including evaluation of induction of chromosomal aberrations, and the ability to monitor MN frequencies in these same tissues is therefore important.
Given the recent emphasis on genotoxic risk characterisation, MOA determination and WOE approaches (84) , the ability to study a wide range of tissues will become increasingly important. However, validated standard protocols (e.g. Organization for Economic Co-operation and Development test guidelines) have not yet been established for most of these tissues, and methods remain primarily research oriented. Even liver, colon, skin and spermatogonia/spermatid MN assays, which have been used relatively frequently for research purposes, are still infrequently used for regulatory purposes. The target cell populations, cell preparation, suitable sampling time(s), cytotoxicity evaluation (dose selection) and/or historical background data are less well established in other tissues, such as lung, bladder, buccal mucosa, nasal epithelium and vagina. Investigation of cell division is a critical issue when studying MN in any tissue. Suitable sampling time(s) after the final treatment varies in different tissues or study designs including the parameters of treatment duration or route of exposure. Further development, especially to establish standard protocols and validation of these MN assays, is highly desirable and will facilitate their increasing application to support more meaningful and relevant assessments of clastogenic/aneugenic risks associated with chemical and physical exposures (1, 2, 17, 21, 83) .
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